Share This Page
Drug Price Trends for NORELGESTROM-EE
✉ Email this page to a colleague
Average Pharmacy Cost for NORELGESTROM-EE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NORELGESTROM-EE 150-35 MCG/DAY | 70710-1190-01 | 37.18127 | EACH | 2025-05-21 |
| NORELGESTROM-EE 150-35 MCG/DAY | 70710-1190-03 | 37.18127 | EACH | 2025-05-21 |
| NORELGESTROM-EE 150-35 MCG/DAY | 70710-1190-03 | 37.17852 | EACH | 2025-04-23 |
| NORELGESTROM-EE 150-35 MCG/DAY | 70710-1190-01 | 37.17852 | EACH | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Norelgestromin and Ethinyl Estradiol (NORELGESTROM-EE)
Introduction
Norelgestromin and ethinyl estradiol, commonly known as NORELGESTROM-EE, is a combined hormonal contraceptive (CHC) available in a transdermal patch form. This analysis will delve into the market dynamics, pricing trends, and future projections for this medication.
Market Overview
The global market for hormonal contraceptives, including NORELGESTROM-EE, is part of the broader endocrinology drugs market. This market has been growing steadily due to several factors:
Increasing Prevalence of Endocrine Disorders
The rising incidence of hormonal imbalances and reproductive health issues has driven the demand for hormonal contraceptives[3].
Growing Awareness and Proactive Screening
Increased awareness about reproductive health and proactive screening for hormonal disorders have contributed to the growth of the market[3].
Technological Advancements
Innovations in drug formulations, such as the development of transdermal patches like NORELGESTROM-EE, have enhanced patient compliance and efficacy[3].
Market Dynamics
Market Drivers
- Growing Aging Population and Lifestyle Changes: These factors contribute to an increase in endocrine disorders, thereby driving the demand for hormonal contraceptives[3].
- Personalized Medicine and Targeted Therapies: The trend towards personalized medicine has led to increased adoption of specific hormonal treatments like NORELGESTROM-EE[3].
Market Restraints
- High Development Costs: The high cost associated with the research and development of endocrinology drugs, including NORELGESTROM-EE, can be a significant barrier[3].
- Stringent Regulatory Requirements: Strict regulatory standards can delay product launches and impact market growth[3].
Pricing and Cost Considerations
Current Pricing
The pricing of NORELGESTROM-EE can vary based on geographical location, insurance coverage, and pharmacy prices. However, it generally falls within the range of other combined hormonal contraceptives.
Cost-Effectiveness
NORELGESTROM-EE offers a convenient and effective form of contraception, which can be cost-effective in the long term by reducing the need for frequent pill intake and minimizing the risk of pregnancy-related costs. However, the initial cost of the patches might be higher compared to some oral contraceptives[2][4].
Pharmacokinetics and Efficacy
The pharmacokinetic profile of NORELGESTROM-EE, which includes higher exposure to ethinyl estradiol (EE) compared to some oral contraceptives, can impact its pricing and market positioning. Studies have shown that the Area Under the Curve (AUC) for EE is approximately 60% higher in women using NORELGESTROM-EE compared to oral contraceptives[2][4].
Risk Factors and Contraindications
The risk of venous thromboembolism (VTE) associated with NORELGESTROM-EE, particularly in women with a BMI ≥ 30 kg/m² or those who smoke, can influence its market acceptance and pricing. These risks may lead to higher costs due to the need for additional monitoring and potential complications[1][4].
Market Projections
Growth Forecast
The endocrinology drugs market, which includes NORELGESTROM-EE, is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.34% from 2024 to 2030, reaching an estimated value of $53.85 billion by 2030[3].
Price Projections
Given the growing demand and technological advancements, the price of NORELGESTROM-EE is likely to remain competitive within the market. However, factors such as increased production costs, regulatory changes, and market competition could influence price fluctuations.
Emerging Markets
Opportunities in emerging markets, where healthcare infrastructure is improving and healthcare spending is increasing, could drive the growth of NORELGESTROM-EE sales. Companies may need to adjust pricing strategies to accommodate these markets while ensuring profitability[3].
Key Takeaways
- Market Growth: The endocrinology drugs market, including NORELGESTROM-EE, is expected to grow significantly due to increasing demand and technological advancements.
- Pricing Considerations: The pricing of NORELGESTROM-EE will be influenced by its pharmacokinetic profile, efficacy, and associated risk factors.
- Market Opportunities: Emerging markets and the trend towards personalized medicine offer significant growth opportunities for NORELGESTROM-EE.
- Regulatory and Cost Factors: Stringent regulatory requirements and high development costs will continue to impact the market dynamics and pricing of NORELGESTROM-EE.
FAQs
Q: What is the primary indication for NORELGESTROM-EE?
A: NORELGESTROM-EE is indicated for the prevention of pregnancy in women with a BMI < 30 kg/m² for whom a combined hormonal contraceptive is appropriate[4].
Q: How does the pharmacokinetic profile of NORELGESTROM-EE compare to oral contraceptives?
A: The AUC for ethinyl estradiol (EE) is approximately 60% higher in women using NORELGESTROM-EE compared to oral contraceptives[2][4].
Q: What are the contraindications for NORELGESTROM-EE?
A: NORELGESTROM-EE is contraindicated in women over 35 years old who smoke, and in women with a BMI ≥ 30 kg/m² due to increased risk of venous thromboembolic events[1][4].
Q: How is the market for NORELGESTROM-EE expected to grow?
A: The market for NORELGESTROM-EE is expected to grow at a CAGR of 7.34% from 2024 to 2030, driven by increasing demand and technological advancements[3].
Q: What are the key factors influencing the pricing of NORELGESTROM-EE?
A: The pricing of NORELGESTROM-EE is influenced by its pharmacokinetic profile, efficacy, associated risk factors, regulatory requirements, and market competition[1][2][4].
Sources
- European Medicines Agency - Evra, INN-norelgestromin/ethinyl estradiol[1]
- FDA Label - ORTHO EVRA (norelgestromin/ethinyl estradiol)[2]
- GlobeNewswire - Endocrinology Drugs Market Analysis by Therapy Area, Distribution Channel - Global Forecast 2025-2030[3]
- Drugs.com - Norelgestromin and Ethinyl Estradiol: Package Insert / Prescribing Info[4]
More… ↓
